

HEROLD-MENDE, CHRISTEL, PROF. DR. RER. NAT.

GENERAL INFORMATION



Professor for Experimental Neurosurgery, Division Head
University Hospital Heidelberg, Department of Neurosurgery
Division of Neurosurgical Research
Im Neuenheimer Feld 400, 69120 Heidelberg, Germany

B04 / D01

ACADEMIC EDUCATION & QUALIFICATION

Year(s)	Education
1990-1994	PhD thesis under the supervision of Prof Schairer, ZMBH Heidelberg
1981-1990	Sports, biology and chemistry, University of Heidelberg

SCIENTIFIC EDUCATION & QUALIFICATION

Year(s)	Education
2012	Professorship in Experimental Neurosurgery, Dpt Neurosurgery Heidelberg
2006	Habilitation in Experimental Cell Biology, University of Heidelberg
1995	Postdoc Ruhr University Bochum, Dpt Applied, Experimental and Interdisciplinary Oncology
1994-1995	Postdoc Div Cytopathology, German Cancer Research Center (DKFZ), Heidelberg

PROFESSIONAL EXPERIENCE

Year(s)	Experience
2012	Professorship in Experimental Neurosurgery, Dpt Neurosurgery Heidelberg
2006-today	Head of the Division of Neurosurgical Research, Dpt Neurosurgery Heidelberg Head of the Molecular Cell Biology Group, ENT Dpt Heidelberg
1996-2006	Head of the Molecular Laboratory, Dpt Neurosurgery Heidelberg Head of the Molecular Cell Biology Group, ENT Dpt Heidelberg

OTHER QUALIFICATIONS/ROLES/RESPONSIBILITIES

Year(s)	
2015 – today	Deputy equal opportunities officer of the Medical Faculty, University of Heidelberg, Germany
2014 – today	Appointed referee for Institutional Grants for the European Union (EU)
2013 – 2016	Member of The Cancer Genome Atlas (TCGA) consortium for lower grade gliomas funded by the National Institute of Health (NIH)
2012 - 2016	Member of the EU-funded COST Action CM 1106: Chemical approaches to targeting drug resistance in cancer stem cells (StemChem), Management Committee Substitute
2010 – today	German Society for Neurosurgery (DGNC), Speaker Selection Committee Member
2010 – today	Deputy Chair, Doctoral Committee Dr. schum., Medical Faculty, University of Heidelberg, Germany
2010 – today	Local coordinator of the Heidelberg University brain tumor tissue bank within the National Center for Tumor Diseases Heidelberg (NCT)
2010 – today	Member of the NCT Advisory Board “Molecular Diagnostics” and of the Advisory Committee of the NCT tissue bank Heidelberg, Germany
2010	EANO IX Poster award in the field of “Immunology and Immunotherapy”
2005	HGF Ideenwettbewerb „Stem cells and glioma“
2005	Clinical Science Award 2004 of the German Society for Immunotherapy
2004	Sybille Assmus Price „Identification of clinical relevant markers in stem cell populations of malignant brain tumors“

SELECTED PUBLICATIONS

1. Dettling S, Stamova S, Warta R, Schnölzer M, Rapp C, Rathinasamy A, Reuss D, Pocha K, Roesch S, Jungk C, Warnken U, Eckstein V, Grabe N, Schramm C, Weigand MA, von Deimling A, Unterberg A, Beckhove P, Herold-Mende C. Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma. **Clin Cancer Res** 2018;24(12):2951-2962
2. Rapp C*, Warta R*, Stamova S, Nowrouzi A, Geisenberger C, Gal Z, Roesch S, Dettling S, Juenger S, Bucur M, Jungk C, DaoTrong P, Ahmadi R, Sahm F, Reuss D, Fermi V, Herpel E, Eckstein V, Grabe N, Schramm C, Weigand MA, Debus J, von Deimling A, Unterberg A, Abdollahi A, Beckhove P, Herold-Mende C. Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. **Acta Neuropathol** 2017;134(2):297–316 * equal contribution
3. Jungk C, Mock A, Exner J, Geisenberger C, Warta R, Capper D, Abdollahi A, Friauf S, Lahrmann B, Grabe N, Beckhove P, von Deimling A, Unterberg A, Herold-Mende C. Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone. **BMC Med** 2016;14(1):170
4. Geisenberger C, Mock A, Warta R, Rapp C, Schwager C, Korshunov A, Nied AK, Capper D, Brors B, Jungk C, Jones D, Collins VP, Ichimura K, Bäcklund LM, Schnabel E, Mittelbron M, Lahrmann B, Zheng S, Verhaak RGW, Grabe N, Pfister SM, Hartmann C, von Deimling A, Debus J, Unterberg A, Abdollahi A, Herold-Mende C. Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. **Acta Neuropathol** 2015;130(3):419–434
5. Beckhove P, Warta R, Lemke B, Stoycheva D, Momburg F, Schnölzer M, Warnken U, Schmitz-Winnenthal H, Ahmadi R, Dyckhoff G, Bucur M, Jünger S, Schueler T, Lennerz V, Woelfel T, Unterberg A, Herold-Mende C. Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation. **J Clin Invest** 2010;120(6):2230–2242
6. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RGW, Aldape KD, Herold-Mende C, et al, Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. **N Engl J Med** 2015;372(26):2481–2498
7. Dutoit V*, Herold-Mende C*, Hilf N, Schoor O, Beckhove P, Bucher J, Dorsch K, Flohr S, Fritsche J, Lewandrowski P, Lohr J, Rammensee HG, Stevanovic S, Trautwein C, Vass V, Walter S, Walker PR, Weinschenk T, Singh-Jasuja H, Dietrich PY. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. **Brain** 2012;135(Pt4):1042–1054 * equal contribution
8. Campos B, Gal Z, Baader A, Schneider T, Sliwinski C, Gassel K, Bageritz J, Grabe N, Beckhove B, Mogler C, Goidts V, Unterberg A, Eckstein V, Herold-Mende C. Aberrant Self-Renewal and Quiescence Contribute to the Malignant Phenotype of Glioblastoma. **J Pathol** 2014;234(1):23-33
9. Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE, Ahmadi R, Lohr J, Dictus C, Gdynia G, Combs SE, Goidts S, Helmke BM, Eckstein V, Roth W, Beckhove P, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende C. Differentiation Therapy Exerts Anti-Tumorigenic, Anti-Angiogenic, Anti-Invasive and Proapoptotic Effects in Brain Tumor Stem Cell-Derived Tumors. **Clin Cancer Res** 2010;16(10):2715-28
10. Steiner HH, Bonsanto M, Beckhove P, Brysch M, Geletneky K, Ahmadi R, Schuele-Freyer R, Kremer P, Ranaie G, Matejic D, Bauer H, Kiessling M, Kunze S, Schirmacher V, Herold-Mende C. Anti-tumor vaccination of patients with glioblastoma multiforme in a case-control study: feasibility and clinical benefit. **J Clin Oncol** 2004;22(21):4272-81

PATENTS

- Rommelaere, Lacroix, SCHLEHOFER, Witt, Deubzer, Kern, Herold-Mende, Geletneky, Leuchs: Use of parvovirus for eliminating cancer stem cells (CSCs) (US9700588B2)
- Martin-Villalba, Kleber, Wiestler, Krammer, Herold-Mende, Sancho-Martinez: Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo (US9309320B2)
- Davioud-Charvet, Becker-Brandenburg, Deborde, Reau, Schirmer, Herold-Mende: Phosphole derivatives complexed with metals, and pharmaceutical uses thereof (US7923434B2)